Please login to the form below

Not currently logged in
Email:
Password:

Apeiron bolsters management board

Peter Llewellyn-Davies joins as its CFO and CBO

Van De WinkelViennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of Peter Llewellyn-Davies.

With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ran his own consulting firm Accellerate Partners.

He said: “Apeiron is currently amongst the most compelling privately owned European biotech companies and I am looking forward to working together with the team to jointly lead Apeiron through the next phase of growth.”

During the course of his career, Llewellyn-Davies supported Medigene’s strategy to form an immunotherapy company and he assisted in initial public offerings for Wilex.

Dr Hans Loibner, chief executive officer, Apeiron, said: “Peter’s expertise, which has been proven by many international capital market transactions, is highly welcome, and he is an ideal addition to support our growth strategy.

“I very much look forward to working hand in hand with him.”

7th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...